A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients.
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs CPI 613 (Primary) ; Gemcitabine
- Indications Cancer; Pancreatic cancer
- Focus Adverse reactions
- 05 Jun 2017 According to Cornerstone Pharmaceuticals media release, Cornerstone Pharmaceuticals changed name to Rafael Pharmaceuticals
- 19 Mar 2017 Status changed from suspended to discontinued.
- 06 Jan 2017 Planned End Date changed from 1 Dec 2014 to 1 Dec 2017.